INTRODUCTION
============

Age-related macular degeneration (AMD) is the leading cause of legal blindness in patients aged 65 and over,[@b1-JOVR-09-044] and is the most common overall cause of blindness in the Western world.[@b2-JOVR-09-044] Choroidal neovascularization (CNV) is the major cause of irreversible blindness in patients with AMD.[@b3-JOVR-09-044] Various factors are suspected to be involved in the development of CNV, such as the vascular endothelial growth factor (VEGF)[@b4-JOVR-09-044] and inflammation.[@b5-JOVR-09-044] Studies have revealed an increased number of lymphocytes, fibroblasts and macrophages within Bruch's membrane in patients with AMD.[@b5-JOVR-09-044],[@b6-JOVR-09-044] Macrophages play a key role in regulating angiogenesis in the retina and choroid.[@b7-JOVR-09-044] One study showed that macrophage depletion reduced CNV size, cellularity and vascularity.[@b8-JOVR-09-044]

Zoledronic acid (ZA) is the most potent form of nitrogen-containing bisphosphonates (BPs).[@b9-JOVR-09-044] Bisphosphonates were developed as powerful inhibitors of osteoclasts and are commonly used to treat and prevent osteoporosis. Recent reports have suggested multiple pharmacologic effects for BPs, such as anti-angiogenic effects via the inhibition of macrophages together with inhibition of production of the pro-angiogenic matrix metalloproteinase (MMP)-9 and VEGF.[@b10-JOVR-09-044]-[@b12-JOVR-09-044] Honda et al[@b3-JOVR-09-044] have shown that oral BPs in CNV associated with AMD and pathological myopia significantly decrease CNV size and improve visual acuity. Therefore, ZA may be an effective treatment modality for ocular neovascularization in the future. To achieve a high concentration of ZA in the eye and to reduce its systemic side effects, intravitreal injection of ZA may be superior to systemic administration for treatment of CNV. However, the safety of intraocular injections of ZA has not yet been evaluated; we therefore performed this study to determine the safe dose for intravitreal injection of ZA in a rat model.

METHODS
=======

**Intravitreal Injections**

Twenty pigmented rats (Razi rats) weighing 250 to 300 grams were divided into five groups (A, B, C, D and E) to receive intravitreal injections of 8, 4, 2 and 1 micrograms (mcg) ZA (Zometa, Novartis, Pharmaceuticals Ltd., UK), or balanced salt solution (BSS) in the left eyes, respectively. The animals were anesthetized using an intraperitoneal injection of ketamine hydrochloride (80 mg/kg) and xylazine hydrochloride (5 mg/kg). Topical anesthesia was achieved with tetracaine. The pupils were dilated with topical tropicamide (0.5%). Intravitreal injections were performed under aseptic conditions using a Hamilton syringe. The animals were treated according to the Association for Research in Vision and Ophthalmology (ARVO) guidelines.

Slit lamp and indirect fundus examinations were performed on all animal eyes at baseline, and one week and one month after intravitreal injections. Animals with corneal or lens opacities prior to the study were excluded.

**Electroretinogram**

All animals were evaluated by electroretinography (ERG) before, and one week and one month after the intravitreal injections. To perform the ERG, the pupils were dilated with 1 drop of tropicamide 0.5%. Standard ERG was recorded in both eyes using corneal electrodes. The reference and ground electrodes were inserted on the frontal area and the ears. The ERG signals were recorded using Retiport/scan 21 electrophysiological diagnostic systems (Roland Consult, Brandenburg an der Havel, Germany). The photopic response, scotopic flash response (maximal combined) and scotopic response after 20 minutes of dark adaptation were recorded simultaneously in both eyes. Amplitudes of \"a\" and \"b\" waves were calculated for each recording before, and one week and one month after the injections. ERG changes were considered significant if b wave amplitudes were reduced by at least 30% from baseline.[@b13-JOVR-09-044]

**Histologic Examination**

One month after intravitreal injections, the rats were euthanized with an overdose of phenobarbital and both eyes were enucleated and fixed in 10% formalin. After bisecting the eyes axially into two calottes and embedding them in paraffin blocks, thin tissue sections were prepared at three different tissue levels (100 microns apart). The sections were stained with hematoxylin & eosin (H&E) and examined under light microscopy (BX41, Olympus, Japan) for presence or absence of retinal hemorrhages, inflammation, necrosis and atrophy, and integrity of the retinal pigment epithelium (RPE) and neurosensory retina.

The retinas of all groups were also tested for glial fibrillary acidic protein (GFAP) immune reactivity (polyclonal rabbit anti-glial fibrillary acidic protein, DAKO, Denmark). GFAP immune reactivity in Muller cells in the injected groups was graded as remarkable and unremarkable, and compared to the controls (BSS group).

RESULTS
=======

Among 20 rats, one rat from group B and 2 rats from group D expired before completion of the study and 17 rats were finally evaluated.

**Clinical Observations**

One week after intravitreal injections, cataracts developed in one eye in group A and 2 eyes in group E, however slit lamp and fundus examination revealed no inflammatory response in any of the eyes.

**Electroretinogram**

Based on the results of photopic, scotopic and flicker responses, no significant change was observed in ERG amplitudes or latency of a and b waves in eyes receiving intravitreal ZA as compared to baseline values, as well as non-injected eyes and BSS injected eyes. These findings indicate no gross retinal functional damage with up to 8 mcg of intravitreal ZA in rat eyes. ERG scotopic b wave amplitudes at baseline, and 1 and 4 weeks after injection are detailed in [Table 1](#t1-JOVR-09-044){ref-type="table"}.

**Histologic Findings**

A summary of histopathologic findings in ZA-injected and control eyes is provided in [Table 1](#t1-JOVR-09-044){ref-type="table"}. None of the eyes in the study groups disclosed intraretinal hemorrhage, inflammation, necrosis or atrophy; furthermore, integrity of retinal layers was well preserved in all cases ([Fig. 1](#f1-JOVR-09-044){ref-type="fig"}). Mild degrees of intravitreal hemorrhage and inflammation were seen in most ZA- as well as BSS-injected eyes (Table-1). GFAP immune reactivity of retinal Muller cells was unremarkable in all ZA-injected eyes as compared to controls ([Figure 1](#f1-JOVR-09-044){ref-type="fig"}).

DISCUSSION
==========

Considering ERG findings and microstructural features observed in the current study, no toxic effect was observed following intravitreal injection of ZA up to 8 mcg in rat eyes. Furthermore, the expression of GFAP was not significantly increased in Muller cells of ZA-injected eyes. This observation, in association with unremarkable histologic features, indicates lack of toxicity of intravitraeal ZA to the rat retina. Mild vitreous hemorrhage and inflammation which was observed in all study groups was related to the intravitreal injection procedure.

CNV is a highly complex, dynamic process and so far little is known about its molecular mechanisms. Multiple factors have been related to CNV formation including inflammatory cells such as lymphocytes and macrophages,[@b14-JOVR-09-044] in addition to VEGF and MMP.[@b4-JOVR-09-044],[@b11-JOVR-09-044],[@b12-JOVR-09-044] Current therapy for CNV associated with AMD consists of repeated intravitreal injection of anti-VEGF antibodies.[@b15-JOVR-09-044] Anti-VEGF therapy requires monthly injections of the agents for a long time to maintain vision, which poses a cumulative risk for ocular and systemic complications. Therefore, new treatment modalities and new intravitreal drugs with more prolonged efficacy seem to be necessary.

Zoledronic acid (ZA) or zoledronate (marketed by Novartis) is a bisphosphonate compound used to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer , as well as to treat osteoporosis .[@b16-JOVR-09-044] Santini et al[@b17-JOVR-09-044] reported that after infusion of ZA, median serum VEGF levels were significantly decreased at days 2, 7 and 21. Serum platelet derived growth factor (PDGF) levels were also significantly decreased by 25% one day after ZA infusion. Recent reports have demonstrated that nitrogen-containing bisphosphonates such as ZA inhibit angiogenesis both *in vitro* and *in vivo*.[@b10-JOVR-09-044] Bisphosphonate may suppress CNV via direct inhibition of vascular endothelial cell proliferation, inhibition of VEGF expression, MMP and the integrin families.[@b10-JOVR-09-044],[@b15-JOVR-09-044] In addition, bisphosphonates are known to control the inflammation induced by macrophages and mononuclear cells which are one of the mechanisms involved in CNV formation.[@b8-JOVR-09-044] Inhibition of macrophages was also shown to prevent intraocular tumor growth in a murine model, probably through inhibition of intra-tumoral macrophage-induced angiogenesis.

Two studies revealed that intra-peritoneal bisphosphonate injection decreased the size of experimental CNV lesions.[@b10-JOVR-09-044],[@b18-JOVR-09-044] One human study showed that oral bisphosphonate maintained visual acuity for at least 6 months and significantly reduced the size of the lesion in patients with CNV due to AMD and pathologic myopia.[@b3-JOVR-09-044]

As mentioned above, systemic use of ZA has anti-angiogenic effects, however information on ocular penetration of systemically administered ZA and intraocular concentration of ZA after oral intake is limited. Intravitreal injection of ZA presumably achieves higher intraocular concentrations leading to greater drug efficacy. In the field of ophthalmology, bisphosphonates have been regarded as drugs that may cause ocular inflammation.[@b19-JOVR-09-044],[@b20-JOVR-09-044] The current series is the first study reporting the safe dose of intravitreal injection of ZA.

In conclusion, our study showed that intravitreal injection of ZA up to a maximum dose of 8 mcg has no toxic retinal effect in rat eyes. The next step would be evaluation of the efficacy of intravitreal ZA on CNV.
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![Unremarkable neurosensory retina following intravitreal injection of 8 mcg ZA (A) and BSS (B), (hematoxylin & eosin stain, magnification ×200). Immunohistochemical staining for glial fibrillary acidic protein (GFAP) was not remarkable with intravitreal injection of either 8 mcg ZA (C) or BSS (D), (magnification ×200). ZA, zoledronic acid; BSS, basal salt solution](JOVR-09-044f1){#f1-JOVR-09-044}

###### 

Mean scotopic ERG-b wave amplitudes and histologic findings in ZA-injected and control eyes

  Groups         Rats   Baseline ERG   1 Week ERG   1 Month ERG   Histologic Findings                       
  -------------- ------ -------------- ------------ ------------- --------------------- ---- ---- ---- ---- ----
  Control (E)    E1     356            352          26            \+                    \-   \-   \-   \+   \+
  E2             398    363            78           \+            \-                    \-   \+   \+   \+   
  E3             142    331            37           \+            \-                    \-   \+   \+   \+   
  E4             312    113            36           \+            \-                    \-   \-   \-   \+   
  1 mcg ZA (D)   D1     112            452          4             \+                    \-   \-   \+   \-   \+
  D2             180    146            69           \+            \-                    \-   \+   \-   \+   
  2 mcg ZA (C)   C1     145            382          120           \+                    \-   \-   \+   \+   \+
  C2             118    448            884          \+            \-                    \-   \-   \-   \+   
  C3             748    277            293          \+            \-                    \-   \+   \-   \+   
  C4             325    238            51           \+            \-                    \-   \-   \+   \+   
  4 mcg ZA (B)   B1     177            317          75            \+                    \-   \-   \+   \-   \+
  B2             220    127            38           \+            \-                    \-   \+   \+   \+   
  B3             402    531            28           \+            \-                    \-   \-   \+   \+   
  8µg ZA (A)     A1     384            135          121           \+                    \-   \-   \-   \-   \+
  A2             330    224            215          \+            \-                    \-   \+   \-   \+   
  A3             104    536            113          \+            \-                    \-   \+   \+   \+   
  A4             284    331            125          \+            \-                    \-   \+   \+   \+   

ZA, zoledronic acid; RH, retinal hemorrhage; RI, retinal inflammation; RN, retinal necrosis; RA, retinal atrophy; VI, vitreous inflammation; VH, vitreous hemorrhage; GFAP, glial fibrillary acidic protein
